6 recruiting, 4 completed, 1 not yet recruiting. 11 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 6, Completed 4, Not yet recruiting 1 |
| Phase 2 | 8 | Recruiting 6, Completed 1, Not yet recruiting 1 |
Follow Rescue medication: new trials by email Literature Review of Rescue medication trials Research Report on Rescue medication
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005) MK-4082, Diltiazem, Rescue medication - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 28 | 2026-07-20 | 2026-11-02 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) I-DXd, Rescue Medication - Oesophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-03-27 | 2026-10-02 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) MK-3120, EV, Pembrolizumab - Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 55 | 2026-02-09 | 2026-10-02 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Pembrolizumab, I-DXd, Leucovorin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 298 | 2025-07-30 | 2026-10-27 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-10-30 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 35 | 2024-12-20 | 2026-11-05 |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin - Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-06-20 | 2026-10-29 |
| Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis ILIT with extract of causal allergen, ILIT with normal saline, Rescue medication for allergic rhinitis - Allergic Rhinitis | Phase 1 | Completed | Gachon University Gil Medical Center | 32 | 2016-07-01 | 2020-02-11 |
| A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) MK-2640, Regular Human Insulin (RHI), Dextrose - Type 1 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 74 | 2014-11-26 | 2019-01-15 |
Esophageal Squamous Cell Carcinoma (2) · Biliary Tract Neoplasms (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Type 1 (1) · Neoplasm Metastasis (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1) · Rhinitis, Allergic (1) · Urinary Bladder Neoplasms (1)
Merck Sharp & Dohme LLC (10) · Gachon University Gil Medical Center (1)
United States (8) · South Korea (7) · Chile (5) · Spain (5) · Taiwan (5) · United Kingdom (5) · Canada (4) · France (4) · Switzerland (4) · Australia (3) · Brazil (3) · China (3) · Israel (3) · Italy (3) · Japan (3)
PMID 19001265, PMID 22464647, PMID 23374268, PMID 24035151, PMID 26706294, PMID 30125349, PMID 34088322
2023 (1), 2025 (1)